Cite
HARVARD Citation
Streinu-Cercel, A. et al. (2022). Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019. Open forum infectious diseases. p. . [Online].